Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-06 Antihistamines
| Cinnarizine and Dimenhydrinate Arlevert® |
|
Formulary
|
Cinnarizine 20 mg, Dimenhydrinate 40 mg Third line **Under review** |
|
Links
Hypersalivation – can hyoscine hydrobromide be used to treat it?- Hypersalivation treatment options
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA Drug Safety Update Dec 2019: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA Dug Safety Update Jan 2020: Ondansetron in pregnancy – small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA update on restricted dose information (Aug 13)
- MHRA: Advice for domperidone (April 2014)
- MHRA: Domperidone: risks of cardiac side effects
- MHRA: Metoclopramide: risk of neurological adverse effects
- MHRA: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- NICE CG150: Headaches in over 12s: diagnosis and management
- NICE CG84: Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management
- NICE TA:919 Rimegepant for treating migraine
- NICE TA906: Rimegepant for preventing migraine
- NICE TA919: Rimegepant for treating migraine
- NICE TA973: Atogepant for preventing migraine
- NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron
- Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
UKMI: Domperidone - New restrictions in GI conditions (May 2014)